You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

VERSED Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Versed, and when can generic versions of Versed launch?

Versed is a drug marketed by HLR and Roche and is included in two NDAs.

The generic ingredient in VERSED is midazolam hydrochloride. There are nine drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the midazolam hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Versed

A generic version of VERSED was approved as midazolam hydrochloride by FRESENIUS KABI USA on June 20th, 2000.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VERSED?
  • What are the global sales for VERSED?
  • What is Average Wholesale Price for VERSED?
Summary for VERSED
Drug patent expirations by year for VERSED
Recent Clinical Trials for VERSED

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Stanford UniversityPhase 2
Lawson Health Research InstitutePhase 3
National Institute of Mental Health (NIMH)Phase 3

See all VERSED clinical trials

US Patents and Regulatory Information for VERSED

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hlr VERSED midazolam hydrochloride INJECTABLE;INJECTION 018654-002 May 26, 1987 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hlr VERSED midazolam hydrochloride INJECTABLE;INJECTION 018654-001 Dec 20, 1985 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Roche VERSED midazolam hydrochloride SYRUP;ORAL 020942-001 Oct 15, 1998 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VERSED

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hlr VERSED midazolam hydrochloride INJECTABLE;INJECTION 018654-002 May 26, 1987 ⤷  Sign Up ⤷  Sign Up
Roche VERSED midazolam hydrochloride SYRUP;ORAL 020942-001 Oct 15, 1998 ⤷  Sign Up ⤷  Sign Up
Hlr VERSED midazolam hydrochloride INJECTABLE;INJECTION 018654-001 Dec 20, 1985 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.